Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure.

Bhatt AS, Liang L, DeVore AD, Fonarow GC, Solomon SD, Vardeny O, Yancy CW, Mentz RJ, Khariton Y, Chan PS, Matsouaka R, Lytle BL, Piña IL, Hernandez AF.

JACC Heart Fail. 2018 Oct;6(10):844-855. doi: 10.1016/j.jchf.2018.04.012. Epub 2018 Aug 8.

PMID:
30098960
2.

High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.

Vardeny O, Udell JA, Joseph J, Farkouh ME, Hernandez AF, McGeer AJ, Talbot HK, Bhatt DL, Cannon CP, Goodman SG, Anand I, DeMets DL, Temte J, Wittes J, Nichol K, Yancy CW, Gaziano JM, Cooper LS, Kim K, Solomon SD.

Am Heart J. 2018 Aug;202:97-103. doi: 10.1016/j.ahj.2018.05.007. Epub 2018 May 23.

PMID:
29909156
3.

When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data Interpretation.

Allen LA, Adler ED, Bayés-Genis A, Brisco-Bacik MA, Chirinos JA, Claggett B, Cook JL, Fang JC, Gustafsson F, Ho CY, Kapur NK, Klewer SE, Kociol RD, Lanfear DE, Vardeny O, Sweitzer NK.

Circ Heart Fail. 2018 Apr;11(4):e005116. doi: 10.1161/CIRCHEARTFAILURE.118.005116. No abstract available.

PMID:
29666074
4.
5.

Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure.

Tran RH, Aldemerdash A, Chang P, Sueta CA, Kaufman B, Asafu-Adjei J, Vardeny O, Daubert E, Alburikan KA, Kucharska-Newton AM, Stearns SC, Rodgers JE.

Pharmacotherapy. 2018 Apr;38(4):406-416. doi: 10.1002/phar.2091. Epub 2018 Mar 22.

PMID:
29423950
6.

Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study.

Vazir A, Claggett B, Cheng S, Skali H, Shah A, Agulair D, Ballantyne CM, Vardeny O, Solomon SD.

JAMA Cardiol. 2018 Mar 1;3(3):200-206. doi: 10.1001/jamacardio.2017.4974.

PMID:
29365021
7.

PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions.

Smith KR, Hsu CC, Berei TJ, Aldemerdash A, Hollis IB, Vardeny O, Rodgers JE.

Pharmacotherapy. 2018 Feb;38(2):284-298. doi: 10.1002/phar.2075. Review.

PMID:
29265423
8.

Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.

Rossignol P, Claggett BL, Liu J, Vardeny O, Pitt B, Zannad F, Solomon S.

Am J Hypertens. 2018 Mar 10;31(4):407-414. doi: 10.1093/ajh/hpx210.

PMID:
29228101
9.

An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality.

Seidelmann SB, Vardeny O, Claggett B, Yu B, Shah AM, Ballantyne CM, Selvin E, MacRae CA, Boerwinkle E, Solomon SD.

J Am Heart Assoc. 2017 Mar 24;6(4). pii: e005257. doi: 10.1161/JAHA.116.005257.

10.

Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.

Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B.

Eur J Heart Fail. 2017 Jun;19(6):792-799. doi: 10.1002/ejhf.688. Epub 2016 Nov 20.

11.

Influenza vaccination: a one-shot deal to reduce cardiovascular events.

Vardeny O, Solomon SD.

Eur Heart J. 2017 Feb 1;38(5):334-337. doi: 10.1093/eurheartj/ehw560. No abstract available.

PMID:
27856498
12.

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD.

JAMA Cardiol. 2017 Jan 1;2(1):79-85. doi: 10.1001/jamacardio.2016.4733.

PMID:
27842179
13.

Pharmacogenomics of heart failure: a systematic review.

Mottet F, Vardeny O, de Denus S.

Pharmacogenomics. 2016 Nov;17(16):1817-1858. Epub 2016 Nov 4. Review.

PMID:
27813451
14.

Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities).

Bello NA, Cheng S, Claggett B, Shah AM, Ndumele CE, Roca GQ, Santos AB, Gupta D, Vardeny O, Aguilar D, Folsom AR, Butler KR, Kitzman DW, Coresh J, Solomon SD.

Circ Heart Fail. 2016 Aug;9(8). pii: e002978. doi: 10.1161/CIRCHEARTFAILURE.115.002978.

15.

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.

Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD; Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators.

Eur J Heart Fail. 2016 Oct;18(10):1228-1234. doi: 10.1002/ejhf.580. Epub 2016 Jun 10.

16.

High-dose influenza vaccine in older adults.

Wang JM, Vardeny O, Zorek JA.

J Am Pharm Assoc (2003). 2016 Jan;56(1):95-7. doi: 10.1016/j.japh.2015.12.001. No abstract available.

PMID:
26802928
17.

Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.

Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJV, Solomon SD; PARADIGM-HF Investigators.

JACC Heart Fail. 2016 Feb;4(2):152-158. doi: 10.1016/j.jchf.2015.10.012. Epub 2015 Dec 30.

18.

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.

Gori M, Gupta DK, Claggett B, Selvin E, Folsom AR, Matsushita K, Bello NA, Cheng S, Shah A, Skali H, Vardeny O, Ni H, Ballantyne CM, Astor BC, Klein BE, Aguilar D, Solomon SD.

Diabetes Care. 2016 May;39(5):677-85. doi: 10.2337/dc15-1760. Epub 2016 Jan 6.

19.

Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”.

Skali H, Shah A, Gupta, Cheng S, Claggett B, Liu J, Bello N, Aguilar D, Vardeny O, Matsushita K, Selvin E, Solomon S.

Circ Heart Fail. 2015 Sep;8(5):1010. No abstract available.

PMID:
26625500
20.

The Role of Neprilysin Inhibitors in Cardiovascular Disease.

Mills J, Vardeny O.

Curr Heart Fail Rep. 2015 Dec;12(6):389-94. doi: 10.1007/s11897-015-0270-8.

PMID:
26466607

Supplemental Content

Loading ...
Support Center